Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Gap Down – What’s Next?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $24.59, but opened at $22.57. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.0760, with a volume of 508,488 shares trading hands.

Wall Street Analyst Weigh In

Several research firms have issued reports on FMS. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. The Goldman Sachs Group cut Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. Zacks Research downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Five analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Down 7.9%

The business has a 50 day simple moving average of $23.34 and a 200 day simple moving average of $24.48. The stock has a market cap of $13.13 billion, a PE ratio of 16.53, a P/E/G ratio of 0.77 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, February 24th. The company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $1.02. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. On average, equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently modified their holdings of FMS. Factory Mutual Insurance Co. acquired a new position in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at $1,769,000. Pzena Investment Management LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% in the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after purchasing an additional 153,870 shares in the last quarter. Todd Asset Management LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 5.2% during the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after purchasing an additional 64,311 shares during the last quarter. ABC Arbitrage SA raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 18.2% during the second quarter. ABC Arbitrage SA now owns 229,375 shares of the company’s stock valued at $6,553,000 after purchasing an additional 35,314 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 26.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock worth $10,684,000 after buying an additional 78,956 shares during the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.